Welcome to Scandion Oncology Q4 report 2022. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answer session, participants are able to ask questions by dialing star 5 on their telephone keypad. Now I will hand the conference over to CEO Francois Martelet and CFO Johnny Stilou. Scandion Oncology since January of this year, meaning about two months. It's actually a pleasure for me to speak with you today on this call, and I will also take the opportunity to briefly introduce myself in a minute or so. With me today, we have our Chief Financial Officer, Johnny Stilou. You know Johnny has been the interim CEO for quite some time. Also Dr. Alfredo Zurlo, our Chief Medical Officer. Johnny and I will be updating you on the development and financial results for the fourth quarter and for the full year of 2022, as well as giving you some insights about recent events. We did maintain our strong operational momentum in the fourth quarter with the PANTAX and CORIST trials progressing as planned. We also maintain a strong financial position with cash on hand to fund the company into 2024. Let me here thank Johnny for a great performance during the interim period. All the credit is due to him. Following our presentation, Johnny and I are happy to take your questions. Please be informed that to best address your questions, we will ask you to state them verbally. It will not be possible to put questions forward in writing. If you have one question, please follow the operator's instructions and ask verbally. Please know that you will have to dial into the call to be able to say the question. This cannot be done through the webcast. Welcome and thank you for your interest in Scandion. Next slide, please. This is the disclaimer slide. Of course, we will not ask you to read it through. Let me remind you that we will be making forward-looking statements during this call, and those are by nature subject to significant risks and uncertainties I described in this disclaimer. Next Slide, please. In our call today, I will first mention about my background and motivation for joining Scandion as a CEO. I will update you on the development in the fourth quarter of 2022, recent events and our clinical trials, followed by an overview of our pipeline. Johnny, our CFO, will provide you with the financial updates, after which we will talk about expected upcoming milestones, events, ending with a reminder of our core strengths as a biotechnology company. Next slide, please. At Scandion, we develop and discover first-in-class innovative medicines aiming at treating cancer which is resistant to current treatment options. We could become a potential leader in reverting cancer drug resistance against treatment, therefore making treatment working better and longer, and thereby potentially reducing, improving, and extending the life of patients who would otherwise would have a high risk of dying from the cancer. Globally, close to 10 million patients die every year from resistant cancer. Around 90% of all clinical trials with small molecules are failing mainly because of drug resistance. This is a massive issue in oncology, in drug development, that has been for the most part ignored by so many pharmaceutical companies. We at Scandion, we have a very small team of very senior level executives who have both the expertise and have the technology internally to help making significant changes in drug resistance. Our technology could potentially be relevant in several different cancer and not only in our main indication, which is colorectal cancer. Please turn to the next slide. As this is the first time that I'm speaking to you as a CEO of Scandion, let me perhaps tell you a little bit about myself, my background, and how I intend to lead Scandion. First of all, let me say that I'm very pleased to have been given the opportunity to join Scandion. We have a fairly straightforward and rather ambitious goal. We want to become a significant player in the field of reverting cancer drug resistance. This is a field I am extremely motivated to work in because of the massive unmet medical needs and the potential benefits we can bring to patients if we are successful. Scandion has a good potential with its R&D platform, promising molecules with exciting preclinical data and a skilled, effective, and committed teams of employees. I have to say that I'm very impressed by the team here. I would like to take the opportunity here to thank them for their efforts in executing relentlessly our clinical trial plans. I have worked myself roughly about 30 years in the pharmaceutical and in the biotech industry. Out of 20 are as a senior level executive. Obviously, you know, this has given me a wide range of experiences in oncology, ranging from preclinical, clinically to commercial and also in business development. I look forward to certainly leveraging this experience in developing Scandion further in order to create long-term value for our shareholders. My immediate focus has been to learn about Scandion from the inside out while ensuring we maintain momentum in executing our clinical trials. We have a very good setup here, meaning that there is a potential first-in-class treatment with SCO-101. My overriding priority is to execute our plans to maximize the value of SCO-101, which will be the basis for creating long-term value. I look forward to serving our shareholders and communicating our progress as we execute on our strategy on a regular basis. Please turn to Slide 6, please. We maintained our strong operational momentum in the fourth quarter of 2022. In October, we have initiated part 3 of the CORIST trial, and PANTAX is also progressing exactly as planned. This is another demonstration of our expertise in conducting challenging international clinical trials involving late stage cancer patients. The fourth quarter also saw me appointed as a new CEO. After the quarter, we further enhanced the executive management team with the appointment of Dr. Jan Stenvang as Chief Scientific Officer. Together with our CMO, Alfredo Zurlo, and our CFO, Johnny Stilou, we now have a very seasoned leadership team for Scandion Oncology in place by all metrics in our industry, and especially as a small biotech company. I'm very pleased, I have to say, to benefiting from the insight of Jan and his contribution into the overall development and management of Scandion Oncology. Jan has led the initial research upon which Scandion Oncology is based. Jan has co-founded the company and has led the research and early development ever since. With more than 20 years of experience in translational cancer research, focusing on drug resistance and biomarker identification, Jan is certainly a tremendous asset to Scandion Oncology as a CSO. We had further good news in January as the European Patent Office issued a favorable patentability opinion regarding our application for an international composition of matter patent of the commercial form of SCO-101. If granted, this patent would extend the commercial potential exclusivity period for SCO-101. This could allow us to expand the development of SCO-101 into new indications and drug combinations. The patent is envisioned to provide protection of the commercial solid form of SCO-101 until its expiry in 2042 or even later. Please turn to the next slide. As mentioned, both CORIST and PANTAX are progressing as planned with a good momentum in the recruitment of patients to both clinical trials. This is, of course, crucial, is and remain our top priority. Given the progress and good momentum, we maintain our expectations of communicating interim results from CORIST 3 in the third quarter of 2023, which means this year, or second half of this year, and from PANTAX in the 1st half of this year. This is, of course, that we don't encounter unforeseen circumstances. I just would like to remind you that CORIST explores SCO-101 as a combination therapy in metastatic colorectal cancer. The ongoing part 3 of the trial is designed to identify the optimal dosing and administration schedule in this setting. We will be also looking at signal of efficacy. In PANTAX, we study SCO-101 as a combination treatment for pancreatic cancer. The interim results will determine optimal dosing called maximum tolerated dose for potential further development in pancreatic cancer. We are also looking obviously at signals of efficacy. Moving on to the next slide. This slide, called pipeline, will give you another view of our pipeline, illustrating that further to CORIST and PANTAX. We are also exploring opportunities with SCO-101 on a preclinical level. We will be also looking at down the road, conducting preclinical activities with our second molecule, SCO-201, in solid tumors. Having said that, I would like to hand over to Johnny for an update on our financial results. Johnny, the floor is yours. Thank you, Francois. Turning to Slide 10 with the financial overview. On this slide, you can see our financial results for the fourth quarter and the full year of 2022. These are completely in line with our expectations as we have carefully invested according to our plans and remain in good cost control. The increase in research and development costs reflect the progression of our two ongoing clinical trials, CORIST and PANTAX. You should also note that our general and administration costs are reduced in the fourth quarter compared to the fourth quarter of 2021, which is also as expected. This is a result of our cost reduction measures, including the reduction of headcounts in the company, which was done to right-size the company according to our strategy and financial position. Next Slide. As you can see on this slide, we maintain a strong financial position with cash on hand to fund the company into 2024, ending 2022 with a cash position of DKK 77.6 million. You can also see that our quarterly spend is reduced compared to both the second and third quarter of the year as a result of our cost and headcount reductions. I will now hand the word back to François. Thank you, Johnny, for a great job again you've been doing as interim CEO and CFO. 2023 will be an exciting year for Scandion, with clinical trial results expected from both PanTAX and CORIST in the first half and the first quarter, respectively. As I mentioned before, we are clearly demonstrating strong execution capabilities, and we are very pleased to be able to confirm these timelines. Next slide, please. In conclusion, we've made good progress in the fourth quarter, and we continue to execute on our strategy and plans. We will continue to focus on execution and maintain the momentum with CORIST and PanTAX. As mentioned before, we have a good setup and the potential to deliver new and better cancer treatments for the patients who so desperately need them, first and foremost with SCO-101. With that, I conclude our presentation. I thank you for your attention. We are now ready to take your questions if you have any. Again, please remember that you can only state your questions verbally. Back to you, the operator. If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial star five again on your telephone keypad. The next question comes from Christian Binder from Redeye. Please go ahead. Hi, thanks so much for taking my question. Just one quick one from me. I understand obviously the focus this year will be on CORIST, but could you elaborate a little bit more on presuming positive data in both part three and part four, how could SCO-101 development look like in metastatic colorectal cancer after that? Well, I think that first of all, you know, we need to get the data. You know, this is absolutely the prerequisite in order to potentially revisit and design or redesign, you know, the, the next step. This is the fundamental answer that I would like to give you unless Frederik would like to make any comments. No. Okay. Okay, got it. Thank you so much. That was all for me. You're welcome. As a reminder, if you wish to ask a question, please dial star five on your telephone keypad. There are no more questions at this time, I hand the conference back to the speakers for any closing comments. Thank you, operator. Thank you for all of you attending this call. Overall, you know, thank you for your support and we look forward to updating you know, in the next coming months about our progress with regard to data. Thank you again. Now you may disconnect your line. Thank you. Bye-bye now.